Who are Soligenix, Inc.'s main suppliers?

Soligenix, Inc. (SNGX) key suppliers include: HY-BIOPHARMA-INC, NEW-YORK-UNIVERSITY, RODMAN, UBC, YEDA-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD and 7 more. View the full supplier network at chainsifter.com/chain/SNGX.

Who are Soligenix, Inc.'s major customers?

Soligenix, Inc. (SNGX) key customers include: SCICLONE-PHARMACEUTICALS-INC. View the full customer network at chainsifter.com/chain/SNGX.

What sector is Soligenix, Inc. in?

Soligenix, Inc. (SNGX) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Soligenix, Inc. Supplier List (SNGX): 12 Verified Suppliers

12Suppliers

1Customers

3Debt Items

2Related Chains

Source-Backed Evidence Depth

Soligenix, Inc. (SNGX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

4Distinct source URLs

10High confidence

0.811Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Soligenix, Inc. Suppliers

Ticker	Name	Confidence	Evidence
HY-BIOPHARMA-INC	HY-BIOPHARMA-INC	92%	We acquired the license agreement for HyBryte™ and related intangible assets, including U.S. patent 8,629,302, properties and rights pursuant to an asset purchase agreement with Hy Biopharma Inc.
NEW-YORK-UNIVERSITY	NEW-YORK-UNIVERSITY	90%	we acquired a worldwide exclusive license agreement with New York University and Yeda Research and Development Company Ltd. for the rights to a novel PDT that utilizes safe visible light for activation
RODMAN	RODMAN	90%	In January 2026, the Company entered into the Rodman Sales Agreement to sell shares of the Company’s common stock from time to time, through ATM sales.
UBC	UBC	90%	The license agreement with UBC provides us with exclusive worldwide rights to manufacture, distribute, market sell and/or license or sublicense products derived or developed from this technology.
YEDA-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD	YEDA-RESEARCH-AND-DEVELOPMENT-COMPANY-LTD	90%	we acquired a worldwide exclusive license agreement with New York University and Yeda Research and Development Company Ltd. for the rights to a novel PDT that utilizes safe visible light for activation
GRTXD	GRTXD	72%	Reciprocal relationship from GRTXD graph: Reciprocal relationship from SNGX graph: Reciprocal relationship from GRTXD graph: Reciprocal relationship from SNGX graph: urers of the drug substances is l…
GRTXD	GRTXD	72%	urers of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternative suppliers, assuming commercially reasonable terms could be reached, the challen…
IPHYF	IPHYF	72%	Reciprocal relationship from IPHYF graph: Reciprocal relationship from SNGX graph: urers of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternat…
IPHYF	IPHYF	72%	urers of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternative suppliers, assuming commercially reasonable terms could be reached, the challen…
INNOVATION-PHARMACEUTICALS-INC	INNOVATION-PHARMACEUTICALS-INC	62%	rers of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternative suppliers, assuming commercially reasonable terms could be reached, the challeng…
PRESENTATION-SOLIGENIX-INC	PRESENTATION-SOLIGENIX-INC	62%	0 Issuance costs associated with warrant inducement — — ( 7,552,457 ) — — ( 7,552,457 ) Warrant modification - incremental fair value — — 7,177,683 — — 7,177,683 Share-bas…
QU-BIOLOGICS-INC	QU-BIOLOGICS-INC	62%	rers of the drug substances is limited. In the event it is necessary or advisable to acquire supplies from alternative suppliers, assuming commercially reasonable terms could be reached, the challeng…

Soligenix, Inc. Customers

Ticker	Name	Confidence	Evidence
SCICLONE-PHARMACEUTICALS-INC	SCICLONE-PHARMACEUTICALS-INC	92%	In September 2016, we and SciClone Pharmaceuticals, Inc. ('SciClone') entered into an exclusive license agreement, pursuant to which we granted rights to SciClone to develop, promote, market, distrib…

Soligenix, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SNGX-DEBT-12644	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.
SNGX-DEBT-12643	Warrants outstanding: 1.35	90%	xbrl warrant detail from xbrl 2025-12-31.
SNGX-DEBT	Debt stack $358,144	90%	Market cache reports total debt of $358,144.

Soligenix, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Soligenix, Inc..

Soligenix, Inc. Ownership

Holder	Name	Confidence	Evidence
SNGX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC	GEODE CAPITAL MANAGEMENT, LLC	90%	13F overlay lists GEODE CAPITAL MANAGEMENT, LLC as top holder; 15 tracked holders.

Soligenix, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
GRTXD	Galera Therapeutics, Inc.	100.00	1	['supplier']
IPHYF	Innate Pharma SA	100.00	1	['supplier']

Soligenix, Inc. Supply Chain